RECRUITING

MyPEEPS LITE Trial

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will use community-informed advertisements and messages through electronic methods to recruit and retain a large (N=2,500), diverse national sample of high-risk young men who have sex with men (YMSM) and non-binary individuals that are assigned male sex at birth, 16-29 years of age to determine the efficacy of the MyPEEPS Mobile intervention on reduced incident HIV infections in comparison to a standard of care condition and to examine the degree to which reduced incident HIV infections occurs in the context of potential multilevel moderators and conceptual mediators. This is key to advancing HIV prevention among HIV-negative US persons at extremely high-risk for HIV seroconversion.

Official Title

MyPEEPS LITE Trial

Quick Facts

Study Start:2025-01-10
Study Completion:2028-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06741631

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:16 Years to 29 Years
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * Be between 16-29 years of age;
  2. * Sex assigned at birth is male and identify gender as male or non-binary;
  3. * Understand and read English;
  4. * Live within US and its territories;
  5. * Own or have access to a smartphone;
  6. * Self-report anal sex with someone who has a penis in the last 12 months; and
  7. * Be HIV-negative or status unknown
  1. * Individuals who identify as transgender

Contacts and Locations

Study Contact

Rebecca Schnall, PhD, MPH
CONTACT
212-342-6886
rb897@columbia.edu

Principal Investigator

Rebecca Schnall, PhD, MPH
PRINCIPAL_INVESTIGATOR
Columbia University
Robert Garofalo, MD, MPH
PRINCIPAL_INVESTIGATOR
Ann & Robert H Lurie Children's Hospital of Chicago
Dustin Duncan, ScD
PRINCIPAL_INVESTIGATOR
Columbia University

Study Locations (Sites)

Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611
United States
Columbia University
New York, New York, 10032
United States

Collaborators and Investigators

Sponsor: Columbia University

  • Rebecca Schnall, PhD, MPH, PRINCIPAL_INVESTIGATOR, Columbia University
  • Robert Garofalo, MD, MPH, PRINCIPAL_INVESTIGATOR, Ann & Robert H Lurie Children's Hospital of Chicago
  • Dustin Duncan, ScD, PRINCIPAL_INVESTIGATOR, Columbia University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-10
Study Completion Date2028-12-01

Study Record Updates

Study Start Date2025-01-10
Study Completion Date2028-12-01

Terms related to this study

Additional Relevant MeSH Terms

  • HIV/AIDS